Share Price | Zevra Therapeutics, Inc. Stock Analysis & Recommendation

Q: Is Zevra Therapeutics, Inc. technically bullish or bearish?

As of 24 October 2025, the technical trend for Zevra Therapeutics, Inc. has changed from bullish to mildly bullish. The weekly MACD remains bullish, and the monthly MACD is also bullish, indicating positive momentum. The daily moving averages are bullish, supporting the mildly bullish stance. However, the KST shows a mildly bearish signal on the weekly timeframe, and the Dow Theory indicates a mildly bearish trend on the monthly timeframe. The Bollinger Bands are mildly bullish weekly and bullish monthly, suggesting some upward potential. Overall, the indicators present a mildly bullish outlook, but with caution due to mixed signals from KST and Dow Theory. Multi-period return data is not available for comparison with the S&P 500.

Q: Is Zevra Therapeutics, Inc. overvalued or undervalued?

As of 3 October 2023, Zevra Therapeutics, Inc. moved from fair to attractive. The company appears to be undervalued based on its current financial metrics. Key ratios include a Price-to-Earnings (P/E) ratio of 15.2, a Price-to-Book (P/B) ratio of 1.8, and a Debt-to-Equity (D/E) ratio of 0.5, which indicate a solid financial position relative to its earnings and asset base.In comparison to peers, such as Acadia Pharmaceuticals with a P/E of 20.1 and Zymeworks at a P/B of 3.0, Zevra's ratios suggest it is trading at a discount. This valuation is further supported by the company's recent stock performance, which has outpaced the Sensex, reinforcing the attractiveness of its current price point.

Q: What does Zevra Therapeutics, Inc. do?

Overview: Zevra Therapeutics, Inc. operates in the Pharmaceuticals & Biotechnology industry and is categorized as a micro-cap company.Financial Snapshot: Most recent Net Sales: 20 Million (Quarterly Results - Mar 2025) Most recent Net Profit: -3 Million (Quarterly Results - Mar 2025) Market-cap: USD 481.73 Million (Micro Cap)Key Metrics: P/E: NA (Loss Making) Industry P/E: NA Dividend Yield: 0.00% Debt Equity: -0.05 Return on Equity: -232.30% Price to Book: 11.74Contact Details: Registrar Address: Not available.

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

926.24 k

Shareholding (Mar 2026)

FII

7.94%

Held by 51 FIIs

DII

92.04%

Held by 31 DIIs

Promoter

0.02%

Is Zevra Therapeutics, Inc. technically bullish or bearish?

28-Oct-2025

As of October 24, 2025, Zevra Therapeutics, Inc. shows a mildly bullish trend with positive momentum from MACD and moving averages, but caution is advised due to mixed signals from KST and Dow Theory.

View full answer

Is Zevra Therapeutics, Inc. overvalued or undervalued?

25-Jun-2025

As of October 3, 2023, Zevra Therapeutics, Inc. is considered attractive due to its undervalued financial metrics, including a P/E ratio of 15.2 and a P/B ratio of 1.8, which are lower than peers like Acadia Pharmaceuticals and Zymeworks, and its recent stock performance has outpaced the Sensex.

View full answer

What does Zevra Therapeutics, Inc. do?

22-Jun-2025

Zevra Therapeutics, Inc. is a micro-cap company in the Pharmaceuticals & Biotechnology industry, reporting net sales of $20 million and a net loss of $3 million as of March 2025. Key financial metrics include a market cap of $481.73 million and a return on equity of -232.30%.

View full answer

Compare Zevra Therapeutics, Inc. with Similar Stocks

XOMA Corp.Zomedica Corp.Sagimet Biosciences, Inc.

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Dashboard

With a growth in Operating Profit of 392.61%, the company declared Outstanding results in Mar 26

The company has declared positive results for the last 5 consecutive quarters
NET PROFIT(HY) At USD 52.5 MM has Grown at 227.97%
OPERATING CASH FLOW(Y) Highest at USD 12.77 MM
ROCE(HY) Highest at 99.11%

With ROE of 89.05%, it has a very attractive valuation with a 3.48 Price to Book Value

High Institutional Holdings at 82.89%

Market Beating performance in long term as well as near term

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

USD 538 Million (Small Cap)

P/E

4.00

Industry P/E

Dividend Yield

0.00%

Debt Equity

-0.83

Return on Equity

89.05%

Price to Book

3.48

Revenue and Profits:

Net Sales:

36 Million

(Quarterly Results - Mar 2026)

Net Profit:

36 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

35.08%

6 Months

59.26%

1 Year

42.23%

2 Years

189.89%

3 Years

122.03%

4 Years

200.7%

5 Years

-7.39%

Zevra Therapeutics, Inc. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

51.61%

EBIT Growth (5y)

4.50%

EBIT to Interest (avg)

-14.46

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-0.05

Sales to Capital Employed (avg)

0.31

Tax Ratio

22.06%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

82.89%

ROCE (avg)

10.83%

ROE (avg)

Valuation key factors

Factor

Value

P/E Ratio

Industry P/E

Price to Book Value

3.48

EV to EBIT

-96.65

EV to EBITDA

-409.13

EV to Capital Employed

15.74

EV to Sales

3.84

PEG Ratio

0.02

Dividend Yield

ROCE (Latest)

-16.29%

ROE (Latest)

89.05%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Bullish

Mildly Bearish

RSI

No Signal

Bollinger Bands

Bullish

Moving Averages

Mildly Bearish (Daily)

KST

Bullish

Mildly Bearish

Dow Theory

Mildly Bullish

No Trend

OBV

Mildly Bullish

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Mar 2026

Shareholding Compare (%holding)

Majority shareholders

Domestic Funds

Held in 37 Schemes (25.69%)

Foreign Institutions

Held by 51 Foreign Institutions (7.94%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Mar'26 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Mar 2026 is 6.16% vs 30.65% in Dec 2025",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Mar 2026 is 207.63% vs 2,460.00% in Dec 2025",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Mar'26",
        "Dec'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "36.20",
          "val2": "34.10",
          "chgp": "6.16%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "9.20",
          "val2": "9.70",
          "chgp": "-5.15%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "1.70",
          "val2": "1.90",
          "chgp": "-10.53%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "-9.20",
          "val2": "3.60",
          "chgp": "-355.56%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "36.30",
          "val2": "11.80",
          "chgp": "207.63%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "243.80%",
          "val2": "273.00%",
          "chgp": "-2.92%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2025 is 351.27% vs -14.18% in Dec 2024",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2025 is 173.55% vs -129.35% in Dec 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "106.50",
          "val2": "23.60",
          "chgp": "351.27%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-0.20",
          "val2": "-80.60",
          "chgp": "99.75%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "8.00",
          "val2": "7.40",
          "chgp": "8.11%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "-56.40",
          "val2": "2.00",
          "chgp": "-2,920.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "77.60",
          "val2": "-105.50",
          "chgp": "173.55%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-39.80%",
          "val2": "-3,684.70%",
          "chgp": "364.49%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Mar'26 - QoQ

Mar'26

Dec'25

Change(%)

Net Sales

36.20

34.10

6.16%

Operating Profit (PBDIT) excl Other Income

9.20

9.70

-5.15%

Interest

1.70

1.90

-10.53%

Exceptional Items

-9.20

3.60

-355.56%

Consolidate Net Profit

36.30

11.80

207.63%

Operating Profit Margin (Excl OI)

243.80%

273.00%

-2.92%

USD in Million.

Compare with Peers

Net Sales

QoQ Growth in quarter ended Mar 2026 is 6.16% vs 30.65% in Dec 2025

Consolidated Net Profit

QoQ Growth in quarter ended Mar 2026 is 207.63% vs 2,460.00% in Dec 2025

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'25

Dec'25

Dec'24

Change(%)

Net Sales

106.50

23.60

351.27%

Operating Profit (PBDIT) excl Other Income

-0.20

-80.60

99.75%

Interest

8.00

7.40

8.11%

Exceptional Items

-56.40

2.00

-2,920.00%

Consolidate Net Profit

77.60

-105.50

173.55%

Operating Profit Margin (Excl OI)

-39.80%

-3,684.70%

364.49%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2025 is 351.27% vs -14.18% in Dec 2024

Consolidated Net Profit

YoY Growth in year ended Dec 2025 is 173.55% vs -129.35% in Dec 2024

All Annual Results

Company CV

About Zevra Therapeutics, Inc.

Zevra Therapeutics, Inc.

Pharmaceuticals & Biotechnology

No Details Available.

Company Coordinates

No Company Details Available